Smith & Nephew plc (LON:SN – Get Free Report) insider Jo Hallas acquired 389 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was acquired at an average cost of GBX 1,384 per share, with a total value of £5,383.76.
Smith & Nephew Trading Up 0.1%
SN opened at GBX 1,382 on Friday. The business has a 50 day simple moving average of GBX 1,204.29 and a 200 day simple moving average of GBX 1,112.67. The company has a market cap of £15.15 billion, a P/E ratio of 49.76, a PEG ratio of 0.46 and a beta of 0.62. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft upped their target price on shares of Smith & Nephew from GBX 1,300 to GBX 1,400 and gave the stock a “hold” rating in a report on Wednesday, August 6th. Berenberg Bank upped their target price on shares of Smith & Nephew from GBX 1,100 to GBX 1,300 and gave the stock a “hold” rating in a report on Thursday, August 7th. Finally, JPMorgan Chase & Co. increased their price target on shares of Smith & Nephew from GBX 1,357 to GBX 1,438 and gave the stock an “overweight” rating in a report on Wednesday, August 6th. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of GBX 1,379.33.
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Featured Articles
- Five stocks we like better than Smith & Nephew
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Snowflake’s Snowballing Business and Robust Stock Price Outlook
- CD Calculator: Certificate of Deposit Calculator
- Chevron Stock Outlook: Dividend Growth Meets Inflation
- What is a Special Dividend?
- Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.